Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biktarvy Switch in HIV-1 with M184V/I Mutation
NCT04040075Phase 4Terminated
- Sponsor
- Southampton Healthcare
- Start
- Jul 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Southampton Healthcare. Started Jul 2019; status: terminated.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04040075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04040075.